코미팜
Financials
Valuation Metrics
코미팜's Market Cap is ₩5468B. At end of 2025 it was ₩5187B. Ranked #430 of 2,436 in KR market (top 18%), #148 of 1,649 on KOSDAQ (top 9%), #51 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 546.76B KRW | KR#430/2,436 Sec#51/234 |
| Revenue | 49.99B KRW | KR#1,780/2,436 Sec#122/234 |
| Net Income | -7.21B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 134.43B KRW | KR#1,546/2,436 Sec#123/234 |
| Net Assets | 73.32B KRW | KR#1,617/2,436 Sec#136/234 |
| Employees | 163 | KR#1,246/2,436 Sec#103/234 |
| Value | ||
| P/B | 7.46x | KR#2,305/2,436 Sec#200/234 |
| P/S | 10.94x | KR#2,282/2,436 Sec#164/234 |
| EV/EBITDA | 324.06x | KR#1,542/2,436 Sec#109/234 |
| FCF Yield | -0.68% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -9.84% | KR#1,897/2,436 Sec#146/234 |
| ROA | -5.37% | KR#1,911/2,436 Sec#144/234 |
| Op. Margin | 3.50% | KR#1,139/2,436 Sec#89/234 |
| Revenue Growth | -17.15% | KR#2,022/2,436 Sec#182/234 |
| Earnings Growth | -1154.28% | KR#1,702/2,436 Sec#116/234 |
| Financial Health | ||
| Debt Ratio | 183.34% | KR#1,565/2,436 Sec#177/234 |
| Total Debt | 39.62B KRW | KR#1,076/2,436 Sec#76/234 |
| FCF | -3.71B KRW | KR#1,438/2,436 Sec#112/234 |
| Cash | 18.58B KRW | KR#1,284/2,436 Sec#96/234 |
| Current Ratio | 1.31x | KR#1,459/2,436 Sec#155/234 |
| Net Debt/EBITDA | 12.01x | KR#1,324/2,436 Sec#96/234 |
| Performance | ||
| 1Y Return | 40.95% | KR#287/2,436 Sec#25/234 |
| 1M Return | -6.33% | KR#1,505/2,436 Sec#152/234 |
| From 52W High | -31.42% | KR#453/2,436 Sec#31/234 |
| 1Y MDD | -35.21% | KR#355/2,436 Sec#25/234 |
| Trading | ||
| Volume | 188,427 shares | KR#598/2,436 Sec#56/234 |
| Foreign Own. | 3.67% | KR#929/2,436 Sec#90/234 |
| Per Share | ||
| EPS | -88 KRW | KR—/2,436 Sec—/234 |
| BPS | 985 KRW | KR#2,285/2,436 Sec#205/234 |
Company Info
Established in 1972 for animal pharmaceutical manufacturing and sales, the company was listed on KOSDAQ in 2001 and produces vaccines and therapeutics at its Siheung-si and Yesan-gun factories. It engages in animal pharmaceutical manufacturing and offers virus and genetic testing research services, conducting overseas business through its subsidiaries. The company expanded its business areas by developing the new drug COMINOX, completing its Osong Bio-complex factory, and obtaining KGMP approval. It is now focused on global sales through a multinational pipeline. COMI Pharm was established in 1972 and is headquartered in Siheung-si, Gyeonggi-do.